Main Article Content
Metaplastic Breast Cancer, Chondroid Differentiation, Triple negative breast cancer
Background: Metaplastic breast cancer (MBC) cancer is a rare subtype of breast carcinoma and carries a worse prognosis. Chondroid differentiation is the rarest among all its histologic subtypes. We report a case of MBC with chondroid differentiation and review its clinicopathological details, genetic basis, and management.
Case presentation: A 56-year female presented with right-sided large breast lump. She noticed this lump 4 months before presenting. Trucut biopsy was suggestive of invasive ductal carcinoma. She underwent breast conservation surgery and histology was consistent with MBC with chondroid differentiation, pT2N3aM0. Tumour was triple-negative for ER, PR, and Her-2- neu receptors. Adjuvant treatment with chemotherapy followed by radiotherapy was given and she has been doing fine during 11 months of follow-up.
Conclusion: The MBC is an uncommon subtype with heterogeneity in biological and morphological features and its knowledge is paramount while evaluating a breast lump. Understanding the pathologic and molecular basis is imperative in developing the targeted therapy to improve outcomes.
2. Yu JI, Choi DH, Huh SJ, Ahn SJ, Lee JS, Shin KH, et al. Unique characteristics and failure patterns of metaplastic breast cancer in contrast to invasive ductal carcinoma: a retrospective multicenter case-control study (KROG 13-07). Clin Breast Cancer. 2015;15(2):e105-15.
3. Barnes P, Boutilier R, Chiasson D, Rayson D. Metaplastic breast carcinoma: clinical–pathologic characteristics and HER2/neu expression. Breast cancer research and treatment. 2005;91(2):173-8.
4. Rayson D, Adjei AA, Suman VJ, Wold LE, Ingle JN. Metaplastic breast cancer: prognosis and response to systemic therapy. Ann Oncol. 1999;10(4):413-9.
5. Fritz A, Percy C, Jack A, Solin L. International classiﬁcation of diseases of oncology. 3rd edn. Geneva: World Health Organization. 2000.
6. Pezzi CM, Patel-Parekh L, Cole K, Franko J, Klimberg VS, Bland K. Characteristics and treatment of metaplastic breast cancer: analysis of 892 cases from the National Cancer Data Base. Annals of surgical oncology. 2007;14(1): 166-73.
7. Huvos AG, Lucas JC, Jr., Foote FW, Jr. Metaplastic breast carcinoma. Rare form of mammary cancer. N Y State J Med. 1973;73(9): 1078-82.
8. Al Sayed AD, El Weshi AN, Tulbah AM, Rahal MM, Ezzat AA. Metaplastic carcinoma of the breast clinical presentation, treatment results and prognostic factors. Acta Oncol. 2006;45(2): 188-95.
9. Myint ZW, Raparla S, Kamugisha LK. Metaplastic breast cancer with chondroid differentiation. Journal of community hospital internal medicine perspectives. 2015;5(4): 28935.
10. Chen I, Lin C, Huang C, Lien H, Hsu C, Kuo W, et al. Lack of efficacy to systemic chemotherapy for treatment of metaplastic carcinoma of the breast in the modern era. Breast cancer research and treatment. 2011;130(1):345-51.
11. Reddy TP, Rosato RR, Li X, Moulder S, Piwnica-Worms H, Chang JC. A comprehensive overview of metaplastic breast cancer: clinical features and molecular aberrations. Breast Cancer Res. 2020;22(1):121.
12.Cancer NGfPIB. Invasive Breast Cancer (Version 3.2020) 2020 [Available from: https://www.nccn.org/patients/guidelines/content/PDF/breast-invasive-patient.pdf.]
13. Rakha EA, Tan PH, Varga Z, Tse GM, Shaaban AM, Climent F, et al. Prognostic factors in metaplastic carcinoma of the breast: a multi-institutional study. Br J Cancer. 2015;112(2): 283-9.
14. Oon ML, Thike AA, Tan SY, Tan PH. Cancer stem cell and epithelial–mesenchymal transition markers predict worse outcome in metaplastic carcinoma of the breast. Breast cancer research and treatment. 2015;150(1):31-41.
15. Gonzalez-Martinez S, Perez-Mies B, Carretero-Barrio I, Palacios-Berraquero ML, Perez-Garcia J, Cortes J, et al. Molecular Features of Metaplastic Breast Carcinoma: An Infrequent Subtype of Triple Negative Breast Carcinoma. Cancers (Basel). 2020;12(7):1832.
Article Statistics :Views : 130 | Downloads : 115 : 15